title: Divergent susceptibilities of human herpesvirus 6 variants to type I interferons.
abstract: Two distinct human herpesvirus 6 (HHV-6) variants infect humans. HHV-6B is the etiologic agent of roseola and is associated with life-threatening neurological diseases, such as encephalitis, as well as organ transplant failure. The epidemiology and disease association for HHV-6A remain ill-defined. Specific anti-HHV-6 drugs do not exist and classic antiherpes drugs have secondary effects that are often problematic for transplant patients. Clinical trials using IFN were also performed with inconclusive results. We investigated the efficacy of type I IFN (alpha/beta) in controlling HHV-6 infection. We report that cells infected with laboratory strains and primary isolates of HHV-6B are resistant to IFN-alpha/beta antiviral actions as a result of improper IFN-stimulated gene (ISGs) expression. In contrast, HHV-6A-infected cells were responsive to IFN-alpha/beta with pronounced antiviral effects observed. Type II IFN (gamma)-signaling was unaltered in cells infected by either variant. The HHV-6B immediate-early 1 (IE1) physically interacts with STAT2 and sequestrates it to the nucleus. As a consequence, IE1B prevents the binding of ISGF3 to IFN-responsive gene promoters, resulting in ISG silencing. In comparison, HHV-6A and its associated IE1 protein displayed marginal ISG inhibitory activity relative to HHV-6B. The ISG inhibitory domain of IE1B mapped to a 41 amino acid region absent from IE1A. Transfer of this IE1B region resulted in a gain of function that conferred ISG inhibitory activity to IE1A. Our work is unique in demonstrating type I IFN signaling defects in HHV-6B-infected cells and highlights a major biological difference between HHV-6 variants.
authors.affiliation: Department of Microbiology-Infectiology-Immunology, Axe Infectiologie et Immunologie, Centre Hospitalier Universitaire de Québec Research Center, Laval University, Quebec, Canada.
authors.forename: Joanna
authors.initials: J
authors.lastname: Jaworska
authors.forename: Annie
authors.initials: A
authors.lastname: Gravel
authors.forename: Louis
authors.initials: L
authors.lastname: Flamand
mesh_terms: D021581:Active Transport, Cell Nucleus; D002478:Cells, Cultured; D015654:Herpesvirus 6, Human / Q000502:physiology*; D006801:Humans; D050834:Interferon-Stimulated Gene Factor 3, gamma Subunit / Q000378:metabolism; D016898:Interferon-alpha / Q000378:metabolism*; D016899:Interferon-beta / Q000378:metabolism*; D011485:Protein Binding; D020218:Response Elements; D050795:STAT2 Transcription Factor / Q000378:metabolism; D015398:Signal Transduction
chemical_list: C494227:IRF9 protein, human; D050834:Interferon-Stimulated Gene Factor 3, gamma Subunit; D016898:Interferon-alpha; D050795:STAT2 Transcription Factor; C494084:STAT2 protein, human; D016899:Interferon-beta
references.citation: Lancet. 1988 May 14;1(8594):1065-7
references.pmid: 2896909
references.citation: Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3840-5
references.pmid: 16497831
references.citation: J Gen Virol. 2004 May;85(Pt 5):1319-1328
references.pmid: 15105549
references.citation: Science. 1986 Oct 31;234(4776):596-601
references.pmid: 2876520
references.citation: Genes Immun. 2001 Oct;2(6):349-55
references.pmid: 11607792
references.citation: Clin Infect Dis. 1998 Jan;26(1):132-7
references.pmid: 9455521
references.citation: J Biol Chem. 1994 Mar 18;269(11):8590-5
references.pmid: 8132584
references.citation: J Virol. 1999 Oct;73(10):8040-52
references.pmid: 10482553
references.citation: J Virol. 2007 Jun;81(11):5737-48
references.pmid: 17376932
references.citation: J Virol. 2008 Nov;82(21):10444-54
references.pmid: 18701593
references.citation: Virology. 2003 Apr 10;308(2):340-53
references.pmid: 12706083
references.citation: Pediatr Infect Dis J. 1992 May;11(5):369-73
references.pmid: 1378586
references.citation: J Virol. 1999 Oct;73(10):8053-63
references.pmid: 10482554
references.citation: Int Immunol. 2005 Nov;17(11):1367-78
references.pmid: 16214811
references.citation: J Cell Sci. 2006 Mar 15;119(Pt 6):1092-104
references.pmid: 16507591
references.citation: J Med Virol. 1996 Jan;48(1):88-94
references.pmid: 8825716
references.citation: Clin Infect Dis. 2005 Apr 1;40(7):932-40
references.pmid: 15824982
references.citation: FEBS Lett. 1998 Dec 11;441(1):106-10
references.pmid: 9877175
references.citation: J Biol Chem. 1997 Aug 8;272(32):20070-6
references.pmid: 9242679
references.citation: Mol Cell Biol. 1989 Nov;9(11):4605-12
references.pmid: 2513475
references.citation: Mult Scler. 2002 May;8(3):237-42
references.pmid: 12120696
references.citation: J Biol Chem. 1996 Mar 8;271(10):5790-4
references.pmid: 8621447
references.citation: J Biol Chem. 2002 May 31;277(22):19679-87
references.pmid: 11901159
references.citation: J Clin Microbiol. 1994 Feb;32(2):473-6
references.pmid: 8150960
references.citation: EMBO Rep. 2003 Jun;4(6):609-15
references.pmid: 12776180
references.citation: J Infect Dis. 1990 Jul;162(1):35-8
references.pmid: 1693942
references.citation: J Infect Dis. 2006 Apr 15;193(8):1063-9
references.pmid: 16544246
references.citation: J Biol Chem. 2004 Sep 17;279(38):39199-206
references.pmid: 15175343
references.citation: Nat Immunol. 2004 Jul;5(7):730-7
references.pmid: 15208624
references.citation: EMBO J. 1998 Nov 16;17(22):6660-9
references.pmid: 9822609
references.citation: Nat Rev Immunol. 2005 May;5(5):375-86
references.pmid: 15864272
references.citation: J Neurovirol. 2007 Dec;13(6):504-12
references.pmid: 18097882
references.citation: Clin Infect Dis. 1995 Oct;21(4):1017-9
references.pmid: 8645791
references.citation: J Clin Microbiol. 1993 Feb;31(2):416-8
references.pmid: 8381815
references.citation: J Med Virol. 2005 Aug;76(4):563-70
references.pmid: 15977239